TY - JOUR
T1 - Transcatheter aortic valve implantation in patients with bicuspid valve morphology
T2 - a roadmap towards standardization
AU - Xiong, Tian Yuan
AU - Ali, Walid Ben
AU - Feng, Yuan
AU - Hayashida, Kentaro
AU - Jilaihawi, Hasan
AU - Latib, Azeem
AU - Lee, Michael Kang Yin
AU - Leon, Martin B.
AU - Makkar, Raj R.
AU - Modine, Thomas
AU - Naber, Christoph
AU - Peng, Yong
AU - Piazza, Nicolo
AU - Reardon, Michael J.
AU - Redwood, Simon
AU - Seth, Ashok
AU - Sondergaard, Lars
AU - Tay, Edgar
AU - Tchetche, Didier
AU - Yin, Wei Hsian
AU - Chen, Mao
AU - Prendergast, Bernard
AU - Mylotte, Darren
N1 - Funding Information:
We thank the National Natural Science Foundation of China (81970325, 82170375 and 82102129) and West China Hospital “1·3·5” Discipline of Excellence Project — “Percutaneous transcatheter aortic valve implantation” and “Mechanisms of aortic stenosis and the clinical applications” for supporting this project, and Yi Zhang (Department of Cardiology, West China Hospital, Sichuan University, China) for assistance with the literature review.
Publisher Copyright:
© 2022, Springer Nature Limited.
PY - 2023/1
Y1 - 2023/1
N2 - Indications for transcatheter aortic valve implantation (TAVI) have expanded in many countries to include patients with aortic stenosis who are at low surgical risk, and a similar expansion to this cohort is anticipated elsewhere in the world, together with an increase in the proportion of patients with bicuspid aortic valve (BAV) morphology as the age of the patients being treated decreases. To date, patients with BAV have been excluded from major randomized trials of TAVI owing to anatomical considerations. As a consequence, BAV has been a relative contraindication to the use of TAVI in international guidelines. Although clinical experience and observational data are accumulating, BAV presents numerous anatomical challenges for successful TAVI, despite advances in device design. Furthermore, in those with BAV, substantial geographical variation exists in patient characteristics, clinical approach and procedural strategy. Therefore, in this Roadmap article, we summarize the existing evidence and provide consensus recommendations from an international group of experts on the application of TAVI in patients with BAV in advance of the anticipated growth in the use of this procedure in this challenging cohort of patients.
AB - Indications for transcatheter aortic valve implantation (TAVI) have expanded in many countries to include patients with aortic stenosis who are at low surgical risk, and a similar expansion to this cohort is anticipated elsewhere in the world, together with an increase in the proportion of patients with bicuspid aortic valve (BAV) morphology as the age of the patients being treated decreases. To date, patients with BAV have been excluded from major randomized trials of TAVI owing to anatomical considerations. As a consequence, BAV has been a relative contraindication to the use of TAVI in international guidelines. Although clinical experience and observational data are accumulating, BAV presents numerous anatomical challenges for successful TAVI, despite advances in device design. Furthermore, in those with BAV, substantial geographical variation exists in patient characteristics, clinical approach and procedural strategy. Therefore, in this Roadmap article, we summarize the existing evidence and provide consensus recommendations from an international group of experts on the application of TAVI in patients with BAV in advance of the anticipated growth in the use of this procedure in this challenging cohort of patients.
UR - http://www.scopus.com/inward/record.url?scp=85132161088&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85132161088&partnerID=8YFLogxK
U2 - 10.1038/s41569-022-00734-5
DO - 10.1038/s41569-022-00734-5
M3 - Article
C2 - 35726019
AN - SCOPUS:85132161088
VL - 20
SP - 52
EP - 67
JO - Nature Reviews Cardiology
JF - Nature Reviews Cardiology
SN - 1759-5002
IS - 1
ER -